文献速递血栓与止血

儿童癌症幸存者静脉血栓栓塞的长期风险:儿童癌症幸存者研究报告

Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
PubMed 文献 · J Clin Oncol · 2018-09-14

儿童癌症幸存者研究纳入24355名5年幸存者和5051名同胞,中位随访21.3年。幸存者晚期静脉血栓栓塞发生率为1.1/1000人年,同胞为0.5/1000人年(RR 2.2,95%CI 1.7-2.8)。女性、顺铂、左旋天冬酰胺酶、肥胖或体重不足、晚期复发或第二恶性肿瘤为危险因素,静脉血栓栓塞与晚期死亡风险升高相关(RR 1.9)。

要点

  • 儿童癌症幸存者晚期静脉血栓栓塞发生率为1.1/1000人年,同胞为0.5/1000人年,RR 2.2。
  • 危险因素包括女性、顺铂、左旋天冬酰胺酶、肥胖或体重不足、晚期复发或第二恶性肿瘤。
  • 下肢骨肉瘤幸存者中,保肢手术和顺铂与晚期静脉血栓栓塞独立相关。

核心结论

  • 儿童癌症幸存者终生静脉血栓栓塞风险增加,静脉血栓栓塞诊断与死亡风险升高相关(RR 1.9,95%CI 1.6-2.3)。
  • 针对肥胖等可能可改变的合并症的干预值得考虑,并对高危幸存者(包括接受顺铂和保肢手术者)进行预防。

研究设计与样本

  • 儿童癌症幸存者研究为多机构队列,纳入24355名5年儿童癌症幸存者(1970-1999年诊断;末次随访中位年龄28.7岁,范围5.6-58.9岁;诊断以来中位随访21.3年,范围5.0-39.2年)和5051名同胞参与者。
  • 主要终点为自我报告的晚期(癌症诊断后≥5年)静脉血栓栓塞,采用多变量分段指数模型估计率比(RR)。

主要发现

  • 幸存者晚期静脉血栓栓塞发生率为1.1/1000人年,同胞为0.5/1000人年(RR 2.2,95%CI 1.7-2.8),35年内每100名幸存者超额2.5例事件。
  • 幸存者中静脉血栓栓塞危险因素:女性(RR 1.3,95%CI 1.1-1.6);顺铂(参照无;1-199 mg/m2:RR 3.0,95%CI 1.4-6.5;200-399 mg/m2:RR 1.9,95%CI 1.0-3.6;≥400 mg/m2:RR 2.0,95%CI 1.2-3.3);左旋天冬酰胺酶(RR 1.3,95%CI 1.0-1.7);肥胖或体重不足(参照BMI 18.5-24.9 kg/m2;BMI≥30.0 kg/m2:RR 1.6,95%CI 1.2-2.0;BMI<18.5 kg/m2:RR 2.4,95%CI 1.7-3.4);晚期癌症复发或第二恶性肿瘤(RR 4.6,95%CI 3.6-5.8)。
  • 下肢骨肉瘤幸存者中,保肢手术(参照截肢;RR 3.1,95%CI 1.2-7.5)和顺铂200-399或≥400 mg/m2(参照无;RR 分别为4.0[95%CI 1.1-14.6]和2.9[95%CI 1.1-8.0])与晚期静脉血栓栓塞独立相关。
  • 静脉血栓栓塞与非外因性晚期死亡风险增加相关(RR 1.9,95%CI 1.6-2.3)。

临床怎么用

  • 作者认为,针对肥胖等可能可改变的合并症的干预值得考虑,并对高危幸存者(包括接受顺铂和保肢手术者)进行预防。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To estimate the incidence of late-occurring venous thromboembolism (VTE) among survivors of childhood cancer and to identify risk factors for VTE to facilitate diagnosis and prevention. Methods The Childhood Cancer Survivor Study is a multi-institutional cohort of 24,355 5-year childhood cancer survivors (diagnosed between 1970 and 1999; median age at last follow-up, 28.7 years [range, 5.6 to 58.9 years]; median follow-up since diagnosis, 21.3 years [range, 5.0 to 39.2 years]) and 5,051 sibling participants. The primary end point was self-reported late (≥ 5 years after cancer diagnosis) VTE. Rate ratios (RRs) were estimated with multivariable piecewise exponential models. Results Late VTE incidence among survivors and siblings was 1.1 and 0.5 events per 1,000 person-years, respectively (RR, 2.2; 95% CI, 1.7 to 2.8), with 2.5 excess events per 100 survivors over 35 years. Among survivors, risk factors for VTE were female sex (RR, 1.3; 95% CI, 1.1 to 1.6), cisplatin (reference none; 1 to 199 mg/m2: RR, 3.0 [95% CI, 1.4 to 6.5]; 200 to 399 mg/m2: RR, 1.9 [95% CI, 1.0 to 3.6]; ≥ 400 mg/m2: RR, 2.0 [95% CI, 1.2 to 3.3]), l-asparaginase (RR, 1.3; 95% CI, 1.0 to 1.7), obesity or underweight (reference body mass index [BMI] 18.5 to 24.9 kg/m2; BMI ≥ 30.0 kg/m2: RR, 1.6 [95% CI, 1.2 to 2.0]; BMI < 18.5 kg/m2: RR, 2.4 [95% CI, 1.7 to 3.4]), and late cancer recurrence or subsequent malignant neoplasm (RR, 4.6; 95% CI, 3.6 to 5.8). Among lower-extremity osteosarcoma survivors, limb salvage (reference amputation; RR, 3.1; 95% CI, 1.2 to 7.5) and cisplatin 200 to 399 or ≥ 400 mg/m2 (reference none; RR, 4.0 [95% CI, 1.1 to 14.6] and 2.9 [95% CI, 1.1 to 8.0], respectively) were independently associated with late VTE. VTE was associated with increased risk for nonexternal cause late mortality (RR, 1.9; 95% CI, 1.6 to 2.3). Conclusion Childhood cancer survivors are at increased risk for VTE across their lifespan and a diagnosis of VTE increases mortality risk. Interventions that target potentially modifiable comorbidities, such as obesity, warrant consideration, with prophylaxis for high-risk survivors, including those treated with cisplatin and limb-sparing approaches.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Madenci AL, Weil BR, Liu Q, et al. Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2018. PMID: 30216123. doi:10.1200/JCO.2018.78.4595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。